Currently, PROTAC technology offers the possibility of inhibiting Tau aggregation by inducing dephosphorylation (42), holding promise as a therapeutic approach for Alzheimer’s disease and other neurodegenerative disorders. This evidence concerns the gene MAPT and Alzheimer disease.